Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.

Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R.

J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1177-8. doi: 10.1136/jnnp-2014-307582. Epub 2014 Apr 3. No abstract available.

PMID:
24700881
2.

JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.

Travasarou M, Marousi S, Papageorgiou E, Karageorgiou CE.

Clin Neurol Neurosurg. 2013 Jun;115(6):827-9. doi: 10.1016/j.clineuro.2012.08.013. Epub 2012 Aug 21. No abstract available.

PMID:
22920632
3.

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.

BMC Neurol. 2016 Jul 12;16:98. doi: 10.1186/s12883-016-0625-0.

4.

Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.

Taieb G, Renard D, Thouvenot E, Servillo G, Castelnovo G.

J Neurol Sci. 2014 Nov 15;346(1-2):364-5. doi: 10.1016/j.jns.2014.09.007. Epub 2014 Sep 16. No abstract available.

PMID:
25241939
5.

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.

Bartt RE.

Curr Opin Neurol. 2006 Aug;19(4):341-9. Review.

PMID:
16914971
6.

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.

Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.

Mult Scler. 2013 Aug;19(9):1226-9. doi: 10.1177/1352458513481010. Epub 2013 Mar 18.

PMID:
23508652
7.

Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?

Maillart E, Louapre C, Lubetzki C, Papeix C.

Mult Scler. 2014 Apr;20(4):505-9. doi: 10.1177/1352458513516530. Epub 2013 Dec 23.

PMID:
24367037
8.

Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.

Havla J, Hohlfeld R, Kümpfel T.

J Neurol. 2014 Jan;261(1):232-4. doi: 10.1007/s00415-013-7191-9. Epub 2013 Nov 26. No abstract available.

PMID:
24276521
9.

[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].

Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.

Duodecim. 2013;129(7):765-70. Finnish.

PMID:
23720945
10.

Early onset of natalizumab-related progressive multifocal leukoencephalopathy.

Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.

Mult Scler. 2011 Nov;17(11):1397-8. doi: 10.1177/1352458511422929. Epub 2011 Sep 7. No abstract available.

PMID:
21900356
11.

Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?

Wattjes MP, Verhoeff L, Zentjens W, Killestein J, van Munster ET, Barkhof F, van Eijk JJ.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1176-7. doi: 10.1136/jnnp-2013-304986. Epub 2013 May 21. No abstract available.

PMID:
23695498
12.

Minimal supportive treatment in natalizumab-related PML in a MS patient.

Lalive PH, Bridel C, Ferfoglia RI, Kaiser L, Du Pasquier R, Barkhof F, Haller S.

J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):354-5. doi: 10.1136/jnnp-2014-308154. Epub 2014 Jun 23. No abstract available.

PMID:
24957322
13.

Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.

Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.

J Neuroimaging. 2014 Jul-Aug;24(4):425-8. doi: 10.1111/jon.12010. Epub 2013 Jan 16.

PMID:
23323645
14.

Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.

Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R.

Mult Scler. 2013 Feb;19(2):249-51. doi: 10.1177/1352458512448268. Epub 2012 May 17.

PMID:
22596228
15.

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.

Hartung HP.

Lancet Neurol. 2009 Jan;8(1):28-31. doi: 10.1016/S1474-4422(08)70281-3. No abstract available.

PMID:
19081511
16.

Natalizumab-associated progressive multifocal leukoencephalopathy.

Mancini N, Clementi M, Burioni R.

N Engl J Med. 2012 Aug 30;367(9):871-2; author reply 872. doi: 10.1056/NEJMc1207116#SA2. No abstract available.

PMID:
22931329
17.

Natalizumab-associated progressive multifocal leukoencephalopathy.

Cervera C.

N Engl J Med. 2012 Aug 30;367(9):871; author reply 872. doi: 10.1056/NEJMc1207116#SA1. No abstract available.

PMID:
22931328
18.

Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.

Baumgartner A, Stich O, Rauer S.

Int J Neurosci. 2012 Jan;122(1):35-9. doi: 10.3109/00207454.2011.622452. Epub 2011 Oct 21.

PMID:
21913869
19.

Natalizumab for multiple sclerosis: a complicated treatment.

Keegan BM.

Lancet Neurol. 2011 Aug;10(8):677-8. doi: 10.1016/S1474-4422(11)70150-8. No abstract available.

PMID:
21777819
20.

Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.

Ropper AH.

N Engl J Med. 2012 May 17;366(20):1938-9. doi: 10.1056/NEJMe1201395. No abstract available. Erratum in: N Engl J Med. 2012 Jul 5;367(1):93.

PMID:
22591300

Supplemental Content

Support Center